GNCA Genocea Biosciences Inc.

3.12
0  0%
Previous Close 3.12
Open 3.11
Price To Book 2.17
Market Cap 81,587,030
Shares 26,149,689
Volume 107,321
Short Ratio
Av. Daily Volume 434,734

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced September 25, 2017 that development will be ceased.
GEN-003
Genital herpes
Topline data did not meet endpoints - September 2015
GEN-004
Universal vaccine candidate against pneumococcus
Phase 1/2 additional immunogenicity data due at ESMO September 27-October 1, 2019. Preliminary data due mid-2020
GEN-009 vaccine
Various cancers

Latest News

  1. Edited Transcript of GNCA earnings conference call or presentation 25-Jul-19 12:30pm GMT
  2. Genocea Provides Corporate Update, Including Second-Quarter 2019 Financial Results
  3. Genocea to Host Quarterly Corporate Update Conference Call & Webcast on July 25th at 8:30 am ET
  4. Need To Know: Genocea Biosciences, Inc. (NASDAQ:GNCA) Insiders Have Been Buying Shares
  5. Are Options Traders Betting on a Big Move in Genocea Biosciences (GNCA) Stock?
  6. Genocea Announces Proposed Public Offering of Common Stock
  7. Genocea Biosciences Rallies 50% On ASCO Presentation
  8. Put Buyers Blast Red-Hot Genocea Biosciences Stock
  9. Genocea Biosciences shares rocket 101% after biotech announces positive data from early-stage trial of cancer vaccine
  10. Genocea’s GEN-009 Vaccine Demonstrates Best-in-Class Immune Responses to ATLAS™-selected Neoantigens in Cancer Patients
  11. The Genocea Biosciences (NASDAQ:GNCA) Share Price Is Down 97% So Some Shareholders Are Very Salty
  12. Genocea’s GEN-009 Clinical Results Presentation Selected by ASCO’s Journal of Clinical Oncology® as a Top 10 Featured Immuno-oncology Abstract
  13. Edited Transcript of GNCA earnings conference call or presentation 30-Apr-19 1:00pm GMT
  14. Genocea Announces Research Collaboration with Iovance to Explore Development of Neoantigen-Targeted TIL (Tumor-Infiltrating Lymphocyte) Products
  15. Genocea Announces Positive Interim Immunogenicity Data from GEN-009 Neoantigen Vaccine Phase 1/2a Clinical Trial
  16. Genocea Biosciences: 1Q Earnings Snapshot
  17. Genocea Provides Corporate Update, Including First-Quarter 2019 Financial Results
  18. Genocea to Host Quarterly Corporate Update Conference Call & Webcast on April 30th at 9:00 am ET
  19. Genocea to Present at 18th Annual Needham Healthcare Conference
  20. Genocea Presents Data at AACR 2019 Supporting Utility of ATLAS™ Platform in Predicting Melanoma Patient Response to Immune Checkpoint Inhibitors